Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis.
“The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life.”
The addition of Vertos Medical’s differentiated portfolio will strengthen Stryker’s impact in interventional solutions to address chronic pain.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$384.85 |
Daily Change: | -5.29 -1.36 |
Daily Volume: | 1,009,285 |
Market Cap: | US$146.710B |
November 19, 2024 November 14, 2024 October 29, 2024 September 20, 2024 September 17, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB